Journal
JOURNAL OF MEDICAL VIROLOGY
Volume 89, Issue 12, Pages 2207-2216Publisher
WILEY
DOI: 10.1002/jmv.24870
Keywords
cytolytic virus activation therapy; EBV DNA load; Epstein-Barr virus; nasopharyngeal carcinoma; PET-scan; targeted cancer therapy; treatment monitoring
Categories
Funding
- KWF Kankerbestrijding [KWF-VU 2010-4809, KWF-VU 2012-5554]
- ZonMw [95110069]
- Dutch Cancer Society
Ask authors/readers for more resources
Undifferentiated nasopharyngeal carcinoma (NPC) is 100% associated with Epstein-Barr virus (EBV). Expression of viral proteins in the tumor cells is highly restricted. EBV reactivation by CytoLytic Virus Activation (CLVA) therapy triggers de novo expression of early viral kinases (PK and TK) and uses antiviral treatment to kill activated cells. The mechanism of tumor elimination by CLVA was analyzed in NPC mouse model using C666.1 cells. Valproic acid (VPA) was combined with gemcitabine (GCb) to stimulate EBV reactivation, followed by antiviral treatment with ganciclovir (GCV). A single cycle of CLVA treatment resulted in specific tumor cell killing as indicated by reduced tumor volume, loss of EBV-positive cells in situ, and paralleled by decreased EBV DNA levels in circulation, which was more pronounced than treatment with GCb alone. In vivo reactivation was confirmed by presence of lytic gene transcripts and proteins in tumors 6 days after GCb/VPA treatment. Virus reactivation was visualized by [I-124]-FIAU accumulation in tumors using PET-scan. This studied showed that CLVA therapy is a potent EBV-specific targeting approach for killing tumor cells. The [I-124]-FIAU appears valuable as PET tracer for studies on CLVA drug dosage and kinetics in vivo, and may find clinical application in treatment monitoring.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available